A piv­ot in­to neoanti­gen im­munother­a­pies was not enough to save Geno­cea Bio­sciences af­ter all.

The 16-year-old biotech said it would be clos­ing down and lay­ing off all re­main­ing em­ploy­ees “ex­cept those deemed nec­es­sary to com­plete an or­der­ly wind down” of op­er­a­tions. It has al­so de­liv­ered a for­mal no­tice to Nas­daq, no­ti­fy­ing the stock ex­change of its in­tent to delist vol­un­tar­i­ly.

The move comes a month af­ter Geno­cea laid off 75% of its work­force and re­vealed it’s look­ing for strate­gic al­ter­na­tives, such as a sale, merg­er or re­verse merg­er. At the end of 2021, it had 74 em­ploy­ees.

In an SEC fil­ing, the com­pa­ny named one of those who will be leav­ing: Thomas Davis, chief med­ical of­fi­cer, whose em­ploy­ment was ter­mi­nat­ed on May 20.

The process did not re­sult in the iden­ti­fi­ca­tion of any vi­able go­ing-con­cern trans­ac­tions. Giv­en the Com­pa­ny’s lim­it­ed re­main­ing re­sources, the Com­pa­ny can­not con­tin­ue op­er­a­tions and be­lieves that the on­ly al­ter­na­tive is an or­der­ly wind-down process. The Com­pa­ny has hired an ad­vi­sor to as­sist in the wind-down process.

As of March 31, the com­pa­ny had $20.1 mil­lion in cash and cash equiv­a­lents, ac­cord­ing to its most re­cent quar­ter­ly re­port. But it al­so has a lease for lab and of­fice space through ear­ly 2025, un­der which it counts about $7.8 mil­lion in min­i­mum lease pay­ments; as well as “out­stand­ing bor­row­ings, net of un­amor­tized debt is­suance costs, of $7.6 mil­lion.” It’s un­clear how the wind­ing down might af­fect those pay­ments.

Co-found­ed in 2006 by Har­vard’s David Sin­clair and Dar­ren Hig­gins, the com­pa­ny ini­tial­ly set out to de­vel­op low-cost vac­cines against a range of virus­es and bac­te­ria. But in 2017, ex­ecs de­cid­ed to ap­ply the same plat­form to look­ing for neoanti­gens that can spur a per­son­al­ized T cell re­sponse against can­cer.

The clin­i­cal da­ta that it of­fered up at AACR proved in­suf­fi­cient for in­vestors, who de­sert­ed the com­pa­ny when it was al­ready fac­ing a cash crunch.

All told, Geno­cea has spent more than $423 mil­lion on its project over the years.

Lonza has been expanding its reach across the globe, bringing sites in China and the US online this year, but now they are looking closer to home for their next major investment.

The Swiss manufacturer on Friday announced plans to construct a large-scale commercial drug fill and finish facility in the town of Stein, Switzerland. The new facility will be delivered through an investment of approximately CHF 500 million, or $519 million, and is expected to be completed in 2026. The facility will also be constructed on the same campus as Lonza’s current clinical drug product facility.

Two weeks ago, Biohaven hit an all-time high in weekly Nurtec prescriptions. CEO Vlad Coric attributes at least some of that success to a new interactive Twitter campaign that encourages patients to free their feed of potential migraine triggers.

Earlier this month, Biohaven in partnership with Twitter launched the #RelieveYourFeed campaign that allows users to customize their app settings based on their migraine triggers.